Navigation Links
New method for reducing tumorigenicity in induced pluripotent stem-cell based therapies
Date:7/23/2014

New Rochelle, NY -- The potential for clinical use of induced pluripotent stem cell (iPSC) technology for transplant-based therapeutic strategies has previously been hindered by the risk of dysregulated cell growth, specifically the development of tumors. The ability to use etoposide treatment to halt teratoma formation in iPSCs for the treatment of heart disease, specifically acute myocardial infarction, is demonstrated in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Stem Cells and Development website.

In the article 'Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy' Saranya Wyles, Andre Terzic, Timothy Nelson, and coauthors, Mayo Clinic (Rochester, MN), discovered a strategy that alone or in conjunction with other methods could significantly reduce the risk of a tumorigenic event occurring. Their work demonstrates how pretreatment with genotoxic etoposide significantly lowered the threat of abnormal growths by removing the contaminated pluripotent cells and establishing an adjunctive therapy to further harness the clinical value of iPSC-derived cardiac regeneration.

"For anyone seeking to exploit iPSC technology in a clinical setting, the Mayo Clinic has described a strategy that significantly mitigates the risk of tumor development. Furthermore, the paper provides benchmark strategies for assessing the localization and persistence of cell-based treatments in a preclinical model," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.


'/>"/>
Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Novel methods may help stem cells survive transplantation into damaged tissues
2. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
3. A new genome editing method brings the possibility of gene therapies closer to reality
4. Food allergies: A new, simple method to track down allergens
5. Comparison study of planting methods shows drilling favorable for organic farming
6. Researchers discover Trojan Horse method of penetrating cellular walls without harm
7. Animal testing methods for endocrine disruptors should change, team argues
8. Frederic Bushman, Ph.D. receives Pioneer Award for advancing therapeutic gene delivery methods
9. Fungal infection control methods for lucky bamboo
10. New method of wormlike motion lets gels wiggle through water
11. Breakthrough method for making Janus or patchy capsules
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New method for reducing tumorigenicity in induced pluripotent stem-cell based therapies
(Date:3/5/2020)... ... March 05, 2020 , ... ... of its Scientific Advisory Board (SAB) comprised of the industry’s key opinion ... cell therapy centers, and private industry. Cytonus is a leading cell-based platform ...
(Date:3/4/2020)... ... March 04, 2020 , ... Vitamin Science, Inc, ... a unique, multi-dimensional nutraceutical formula for ocular blue light protection. , VisiVite ... to increase the retina’s healthy pigmentation and improve the eye’s management of high ...
(Date:3/3/2020)... LAGUNA HILLS, Calif. (PRWEB) , ... March 03, 2020 , ... ... 300 spinal levels with the dualX Expanding Interbody Fusion System. , The ... in Fresno, CA. After the case Dr. Najafi noted, “dualX has completely changed ...
Breaking Biology News(10 mins):
(Date:3/4/2020)... ... March 04, 2020 , ... ... services, today announced the launch of its FleXpress™ high-throughput recombinant antibody production ... of antibodies at 80 ml scale. All production occurs in Absolute Antibody’s ...
(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... ... serving the pharmaceutical, biotech and medical device industries, was recognized by INC. 5,000 ... puts forward annual lists to note industry leaders greatly impacting their spheres of ...
(Date:3/2/2020)... ... , ... McBee, Moore and Vanik IP, LLC (MMV IP) has been ranked ... Organics. , According to statistics compiled by Harrity Anaytics, MMV IP was listed as ... 1600 during 2019. Technology center 1600 at the US Patent Office (“USPTO”) specializes in ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its leading research on ... of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. , ... complex carbohydrates are indigestible and therefore function as a prebiotic by promoting early ...
Breaking Biology Technology: